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Transforming growth factor b1 treatment of kerati-
nocytes results in a suppression of differentiation, an
induction of extracellular matrix production, and a
suppression of growth. In this study we utilized mar-
kers speci®c for each of these functions to explore
the signaling pathways involved in mediating these
transforming-growth-factor-b1-induced activities. In
the ®rst instance, we found that the induction of
extracellular matrix production (characterized by
3TP-Lux reporter activity) was induced in both kera-
tinocytes and a keratinocyte-derived carcinoma cell
line, SCC25, in a dose-dependent manner.
Furthermore, transforming growth factor b1 also
suppressed the differentiation-speci®c marker gene,
transglutaminase type 1, in both keratinocytes and
SCC25 cells. In contrast, transforming growth factor
b1 inhibited proliferation of keratinocytes but did
not cause growth inhibition in the SCC25 cells.
Transforming-growth-factor-b1-induced growth
inhibition of keratinocytes was characterized by
decreases in DNA synthesis, accumulation of hypo-
phosphorylated Rb, and the inhibition of the
E2F:Rb-responsive promoter, cdc2, and an induction
of the p21 promoter. When the negative regulator of
transforming growth factor b1 signaling, SMAD7,
was overexpressed in keratinocytes it could prevent
transforming-growth-factor-b1-induced activation of
the 3TP-Lux and the p21 promoter. SMAD7 could
also prevent the suppression of the transglutaminase
type 1 by transforming growth factor b1 but it could
not inhibit the repression of the cdc2 promoter.
These data indicate that the induction of 3TP-Lux
and p21 and the suppression of transglutaminase type
1 are mediated by a different proximate signaling
pathway to that regulating the suppression of the
cdc2 gene. Combined, these data indicate that the
regulation of transforming growth factor b1 actions
are complex and involve multiple signaling path-
ways. Key words: SMAD7/squamous carcinoma/squamous
differentiation. J Invest Dermatol 116:266±274, 2001
T
here is a growing body of evidence to suggest that the
maintenance of epidermal growth and differentiation
is controlled, in vivo, by the combined action of
positive and negative factors. In the instance of the
epidermis, the likely candidates to ful®ll these roles
are the mitogen, transforming growth factor a (TGF-a), and the
tumor suppressor, transforming growth factor b1 (TGF-b1).
Recent experimental evidence indicates that overexpression of
either cytokine results in perturbations to epidermal growth and
differentiation. For instance, transgenic mice overexpressing TGF-
a in skin are characterized by epidermal hyperplasia and a
propensity for skin tumor formation (Vassar and Fuchs, 1991;
Dominey et al, 1993; Wang et al, 1995). On the other hand,
overexpression of TGF-b1 in the skin of transgenic mice results in
the inhibition of epidermal proliferation and ultimately death (Cui
et al, 1995). Furthermore, transgenic mice in which a dominant
negative mutant of the type II TGF-b receptor was expressed
speci®cally in the skin were characterized by epidermal hyperplasia
(Wang et al, 1997). Thus, both TGF-a and TGF-b appear to be
key regulators responsible for maintaining the proliferation rate of
keratinocytes in vivo.
Earlier studies with cultured keratinocytes have shown that
TGF-b1 (i) suppresses keratinocyte proliferation (Pietenpol et al,
1990a, b; Saunders and Jetten, 1994; Alexandrow and Moses,
1995); (ii) induces extracellular matrix (ECM) production (Voll-
berg et al, 1991); and (iii) suppresses differentiation (Saunders and
Jetten, 1994). This combination of effects would seem reasonable as
this would allow the epidermal basal cells considerable ``reserve''
proliferative potential to respond to injury whilst actively
maintaining an undifferentiated phenotype. As basal keratinocytes
are responsible, in part, for the production of their basement
membrane, the effects on the ECM would appear self-evident. The
same rationale may be applied to the role of TGF-b1 in the
wounded epidermis.
Given that TGF-b1 treatment of keratinocytes results in three
different biologic outcomes (growth suppression, differentiation
suppression, and ECM induction) it is of interest to de®ne the
signaling pathway(s) that mediate these seemingly disparate effects.
Until recently, the events linking the activation of the plasma-
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membrane-bound TGF-b receptor to nuclear transcriptional
events, and hence suppression of growth and differentiation, were
unclear. Recent studies identifying the SMAD family of signal
transducers, however, have allowed a reasonably clear picture of
how TGF-b1 receptor activation can initiate transcriptional
activation of TGF-b1-responsive genes in other cell systems
(Massague, 1996; Alevizopoulos and Mermod, 1997; Heldin et al,
1997; Wrana and Pawson, 1997). A current model for TGF-b1
signal transduction is that receptor occupation leads to phosphor-
ylation and activation of the type I receptor by the type II receptor
(Bassing et al, 1994; ten Dijke et al, 1994; Wieser et al, 1995; Feng
and Derynck, 1997). This results in phosphorylation of either
SMAD2 or SMAD3 and subsequent binding of the phosphorylated
SMAD protein to a cytoplasmic SMAD4 protein (Zhang et al,
1996). This complex is then translocated into the nucleus where it
associates with DNA binding factors such as FAST-1 and trans-
activates genes with TGF-b1 response elements (Massague, 1996).
A recent report suggests that TGF-b1-mediated trans-activation
may also be mediated directly by SMAD3/SMAD4 heterodimers
(Dennier et al, 1998). One of the activated genes may be an
inhibitory SMAD protein such as SMAD6 or SMAD7 (Imamura
et al, 1997; Nakao et al, 1997; Afrakhte et al, 1998). SMAD6 or
SMAD7 operate as negative regulators of the signal transduction
pathway by inhibiting receptor-mediated activation of the SMAD2
or SMAD3 signal transducers. This signaling pathway has been
shown to be conserved in a number of cell systems and is
de®nitively associated with the activation of transcription via TGF-
b-responsive elements in the plasminogen activator inhibitor 1
gene (PAI-1; Hayashi et al, 1997; Imamura et al, 1997; Nakao et al,
1997; Whitman, 1997). The role of the SMAD proteins, if any,
however, in the regulation of other TGF-b1-mediated effects such
as suppression of growth or differentiation in keratinocytes is less
clear. The importance of determining the events by which TGF-b1
mediates its effects on keratinocytes takes on greater signi®cance in
light of the data implicating defects in TGF-b1 regulation in
various tumors. In fact, the original cloning of the human SMAD4
gene was as a tumor suppressor gene involved in pancreatic cancer
(Hahn et al, 1996). Since then various tumor cell lines and patient
tumors have been examined for mutations within the TGF-b1
signaling pathway (Park et al, 1994; Antar et al, 1995; Reiss et al,
1997; De et al, 1998; Lu et al, 1998). Of the SMAD proteins studied
to date only SMAD2 and SMAD4 have been found to carry
mutations in a subset of tumors (Riggins et al, 1997).
With the exception of a recent study with activin signaling in B
cells (Ishisaki et al, 1998), there have been no de®nitive studies
linking the SMAD signaling pathway with either TGF-b1-
mediated suppression of growth or squamous differentiation. In
fact, there is considerable evidence to suggest that the signaling
pathways that mediate the effects of TGF-b on growth and TGF-
b-mediated trans-activation are functionally independent. For
instance, earlier studies by Chen et al (1993) reported that a
truncated type II TGF-b receptor was associated with a loss of
TGF-b1-mediated growth inhibition whereas PAI-1 trans-activa-
tion was maintained. Furthermore, it has been reported that the loss
of TGF-b1-mediated growth inhibition, but not PAI-1 trans-
activation, in lesional vascular endothelial cells was attributable to a
loss of type II TGF-b receptor expression (McCaffrey et al, 1995).
Whether different TGF-b signaling pathways are responsible for
the control of growth inhibition and PAI-1 induction, however,
remains unclear (Cui et al, 1995; Massague, 1996; Heldin et al,
1997).
In this study we speci®cally looked at whether (i) the suppression
of proliferation, (ii) the suppression of differentiation, and (iii) the
induction of ECM by TGF-b1 utilized similar signaling pathways.
In order to do this we used well-established markers such as the
phosphorylation status of Rb (Dyson, 1998), cdc2 promoter
activity (Dahler et al, 1998; Dicker et al, in press), and p21
promoter activity (Datto et al, 1995; Li et al, 1998; Moustakas and
Kardassis, 1998) as our markers of proliferation, the expression of
transglutaminase type 1 (TG 1) as our marker of differentiation
(Saunders et al, 1993b; Saunders and Jetten, 1994; Dicker et al, in
press), and the activation of the 3TP-Lux reporter (derived from
the PAI-1 promoter) as our marker of ECM production (Wrana
et al, 1992). We report that the suppression of differentiation and
the induction of PAI-1 are mediated by an SMAD7-inhibitable
signaling pathway(s) whereas TGF-b1-mediated growth inhibition
involves multiple signaling pathways, one of which is SMAD7
insensitive (cdc2 suppression) and another of which is SMAD7
sensitive (p21 induction).
EXPERIMENTAL PROCEDURES
Cell culture and DNA synthesis assays Human epidermal
keratinocytes were isolated and cultured from neonatal foreskins
following circumcision (Saunders et al, 1993a; Jones et al, 1997). The
keratinocyte-derived sqamous carcinoma cell line, SCC25, was originally
isolated from a squamous carcinoma of the tongue and was purchased from
the American Type Culture Collection (Rockville, MD) and cultured in
Ham's F12:Dulbecco's modi®ed Eagle's medium (1:1, vol:vol) containing
10% serum and supplemented with penicillin/streptomycin (10,000 U
per ml; Life Technologies, Sydney, Australia; Jones et al, 1997; Dicker et al,
in press). When required, DNA synthesis was estimated by the
incorporation of [3H] methyl thymidine into cellular DNA as described
previously (Saunders et al, 1993a, 1999a). TGF-b1 and 12-O-
tetradecanoylphorbol-13-acetate (TPA) were purchased from Sigma
(Sydney, Australia) and interferon-g (IFN-g) was purchased from Life
Technologies.
Protein isolation and western blotting Cells, grown in 75 cm2 ¯asks,
were trypsinized and rinsed with cold phosphate-buffered saline (PBS) and
collected by centrifugation (200g for 2 min). Cells were immediately
resuspended in 6 3 protein sample buffer (Saunders et al, 1999b), boiled for
3 min, and stored at ±70°C until required. When required, 20 mg of protein
was then boiled for 3 min and electrophoresed on a 7.5% sodium dodecyl
sulfate polyacrylamide gel (SDS-PAGE). The proteins were transferred to a
PVDF membrane and blocked for 6 h at room temperature in 3% skim
milk powder (wt/vol) in PBST (PBS + 0.05% Tween-20, vol/vol). A
rabbit polyclonal antibody against human Rb (sc-50; Santa Cruz
Biotechnology, Brisbane, Australia) or a rabbit polyclonal antibody
against human cdc2 (Ab-1; Oncogene Science, Melbourne, Australia)
was then incubated with the blot overnight at 4°C in 3% skim milk powder
in PBST. Blots were washed in PBST and incubated with horseradish
peroxidase conjugated antirabbit monoclonal antibody (Selenus, Sydney,
Australia) for 2 h at room temperature in 3% skim milk powder in PBST.
Blots were then washed thoroughly with PBST and the speci®c proteins
were visualized by ECL detection (Amersham, Sydney, Australia).
Transfection and reporter assays The 3TP-Lux reporter gene
contains three TGF-b1-responsive elements from the PAI-1 promoter
linked to the ®re¯y luciferase gene (Wrana et al, 1992). A 949 bp fragment
of the human cdc2 promoter directing expression of a CAT reporter gene
(cdc2-CAT) has been described previously (Dalton, 1992; Dahler et al,
1998). The cdc2-CAT construct contains an E2F:Rb-responsive element
at ±125 bp (Dalton, 1992). A 291 bp fragment of the human p21 promoter
(Zeng et al, 1997) containing a TGF-b1-responsive element (Datto et al,
1995; Moustakas and Kardassis, 1998) driving the expression of a luciferase
reporter gene has been described previously. A squamous differentiation-
speci®c 2.9 kb fragment of the rabbit transglutaminase type I promoter
coupled to a luciferase reporter gene has also been described (Saunders et al,
1993b; Medvedev et al, 1999). The b-actin CAT reporter gene (Saunders
et al, 1993b) or a b-actin luciferase reporter gene (Dahler et al, 1998) were
used to normalize for transfection ef®ciency. Transient transfections of
human epidermal keratinocytes and SCC25 cells were performed on 30%
con¯uent cultures and assayed for reporter activity 48 h post-transfection.
For human epidermal keratinocytes, 10 cm2 wells were rinsed once with
minimal serum-free medium (SFM; Life Technologies) and transfected
with 1 mg reporter (e.g., 3TP-Lux, p21, or cdc2-CAT) plus 0.3 mg b-actin
CAT/luciferase and 4 ml lipofectamine reagent (Life Technologies). The
lipofectamine and the individual plasmids were prepared separately in
100 ml of minimal SFM each, mixed together, and then left for 30 min at
room temperature. These solutions were mixed with 0.8 ml minimal SFM
per transfection. The diluted complexes were added to the rinsed cells for
5 h at 37°C at which time the medium was replaced with complete SFM.
In some instances cotransfections with an expression plasmid coding for
SMAD7 (Nakao et al, 1997) were carried out in human epidermal
keratinocytes. These were performed in a similar manner to that described
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above except that 0.3 mg of CMV SMAD7 or the control vector pCDNA3
(InVitrogen, Melbourne, Australia) were included in the transfection.
SCC25 cells were transfected by the calcium phosphate method. Cells
were fed with 1 ml complete 1:1 medium (Jones et al, 1997) immediately
prior to transfection. For each well, 2 mg 3TP-Lux and 2 mg b-actin CAT
were diluted to 100 ml with sterile water and 25 ml of 2.5 M CaCl2 was
added. The DNA-CaCl2 mix was added dropwise to 125 ml 2 3 HEPES-
buffered saline (pH 7.05) being bubbled through by a mechanical pipette
and the solution was brie¯y vortexed. The precipitate was allowed to form
for 30 min at room temperature and was overlaid onto the fed cells. Cells
were incubated for 8 h and then shocked for 3 min at room temperature
with 15% glycerol (vol/vol), followed by three PBS washes. Cells were
refed with 2 ml complete 1:1 medium and incubated for 48 h.
Chloramphenicol acetyltransferase and luciferase reporter assays have
been described previously (Saunders et al, 1993b; Dahler et al, 1998;
Medvedev et al, 1999). In instances where dose-response curves were
analyzed, data were subjected to nonlinear least squares regression analysis
and ®tted to the equation e = (Emax 3 Ec50)/(L + Ec50) using the software
analysis program Prism (GraphPad, U.S.A.), where e is the percentage
induction above untreated cells, Emax is the maximal effect, L is the TGF-
b1 concentration (ng per ml), and Ec50 is the concentration of TGF-b1 at
which half maximal response was observed.
RNA isolation, northern blotting, and reverse transcriptase
polymerase chain reaction (RT-PCR) The isolation of total cellular
RNA and the detection by northern blotting has been described previously
(Saunders et al, 1993b; Saunders and Jetten, 1994). Generation of a probe
for TG 1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has
been described previously (Saunders et al, 1993b). Probes for the detection
of the type I or type II TGF-b receptors were generated by PCR
ampli®cation using previously described primers (Guo and Kyprianou,
1998). A probe for the detection of SMAD7 was generated from a BamH1/
EcoR1 restriction fragment from the corresponding expression plasmid. To
normalize for loading inequalities northern blots were also probed with
GAPDH (Saunders et al, 1993b). In experiments addressing TG 1 mRNA
half-life, the blots were analyzed by phosphorimage analysis as described
earlier (Saunders et al, 1998; 1999a). In all other instances the transcript
expression was visualized by exposure to Kodak XAR5 ®lm (Kodak,
Sydney, Australia).
The analysis of mRNA expression by RT-PCR has been described
(Jones et al, 1997; Saunders et al, 1998, 1999a). RT-PCR analysis was used
to examine the expression of the differentiation-speci®c gene TG 1 and the
housekeeping gene actin in human epidermal keratinocytes following
¯uorescence-activated cell sorting (FACS) of transfected cell populations.
FACS analysis FACS was used to purify trasnfected cells out of
keratinocyte cultures using an EPICS Elite ESP ¯ow cytometer (Coulter,
Hiateah, FL). FACS analysis was performed in experiments determining the
ability of SMAD7 to inhibit the suppression of differentiation
(characterized by TG 1 mRNA expression).
In studies examining the SMAD7 sensitivity of the suppression of TG 1
by TGF-b1, human epidermal keratinocyte cultures (1 3 25 cm2 ¯ask per
condition) were treated with TPA (50 ng per ml) for 16 h at which time
they were cotransfected with either the pCDNA3 vector (2.6 mg) or the
SMAD7 expression vector (2.6 mg) plus an expression vector coding for
green ¯uorescent protein (0.8 mg, CMV-GFP; Clontech, Sydney,
Australia). Five hours after transfection with lipofectamine, the cells were
refed with medium containing TPA (50 ng per ml) or TPA (50 ng per ml) +
TGF-b1 (20 ng per ml). Twenty-four hours later the human epidermal
keratinocytes were trypsinized and passed through 75 mm gauze into FACS
tubes. Human epidermal keratinocytes expressing GFP were then sorted
and collected into Eppendorf tubes and centrifuged (10 s at 10,000g). The
cell pellet consisting of between 4000 and 10,000 cells was subjected to
RNA isolation and the equivalent of 103 cells were used for RT-PCR
analysis of TG 1 and actin mRNA expression. RT-PCR analysis was
performed under linear conditions with respect to cycle number to assure
quantitative determination of gene expression.
RESULTS
SCC25 cells possess an intact SMAD-dependent signaling
pathway TGF-b1 caused a dose-dependent decrease in human
epidermal keratinocyte proliferation (Ec50 = 3.2 6 1.3 ng per ml;
Fig 1A). Consistent with an earlier report (Shipley et al, 1986), a
keratinocyte-derived carcinoma cell line, SCC25, was resistant to
TGF-b1-induced growth inhibition up to a concentration of 30 ng
per ml (Fig 1B). As loss of TGF-b1 responsiveness in other
carcinoma cell lines has been previously shown to be associated
with defects in TGF-b1 receptor/SMAD signaling (Park et al,
1994; Antar et al, 1995; Reiss et al, 1997), we examined the ability
of the human epidermal keratinocytes and SCC25 cells to activate
the TGF-b1-responsive elements contained in the 3TP-Lux
reporter construct. The 3TP-Lux reporter gene contains three
TGF-b1-responsive elements from the promoter of the ECM
protein, PAI-1, linked to the ®re¯y luciferase gene (Wrana et al,
1992). Both human epidermal keratinocytes and SCC25 cells were
able to induce 3TP-Lux activity following TGF-b1 treatment
(Fig 1C). In fact, the SCC25 cells (Fig 1B) appeared more sensitive
Figure 1. Human epidermal keratinocytes and SCC25 cells activate
3TP-Lux in response to TGF-b1. Proliferating human epidermal
keratinocytes (A) or SCC25 cells (B) were incubated with varying
concentrations of TGF-b1 for 48 h, following which DNA synthesis (d)
was estimated by a thymidine incorporation assay (dpm incorporated per mg
protein) or 3TP-Lux activity was assayed (s). Data are presented as a
percentage of the untreated cells. Data points represent mean 6 SEM. (C)
TGF-b1-mediated trans-activation was measured in human epidermal
keratinocytes or SCC25 cells. Cells were transfected with reporter
constructs as described in Experimental Procedures and were then treated
for 48 h with (+TGF-b1; 20 ng per ml) or without (±TGF-b1) TGF-b1
following which luciferase activity was estimated. Data represent mean
6 SEM of at least three determinations.
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to TGF-b1 [Emax = 356 6 32; Ec50 = 0.01 6 0.06 ng per ml;
degrees of freedom (df) = 16] than were the human epidermal
keratinocytes (Fig 1A; Emax = 365 6 26, Ec50 = 0.41 6 0.16 ng
per ml; df = 16) with respect to 3TP-Lux activation. This ®nding
was signi®cant as it indicated that both human epidermal
keratinocytes and SCC25 cells had an intact receptor/SMAD
signaling pathway. This is despite the observation that the SCC25
cells express very little type II receptor mRNA but similar amounts
of type I receptor mRNA compared with human epidermal
keratinocytes (Fig 2). These data suggested that (i) TGF-b1-
induced growth inhibition in human epidermal keratinocytes was
mediated by events downstream of TGF-b1-mediated trans-
activation or (ii) that the signaling pathway mediating growth
inhibition was independent of that required for SMAD-mediated
trans-activation.
To examine the possibility of an alternative growth inhibitory
pathway in human epidermal keratinocytes we assayed for the
phosphorylation status of Rb in TGF-b1-treated human epidermal
keratinocytes and SCC25 cells (Fig 3A±C). TGF-b1 induced a
time-dependent decrease in DNA synthesis in human epidermal
keratinocytes (Fig 3A) but not in SCC25 cells (Fig 3B). TGF-b1
treatment also caused a marked reduction in both the hyperpho-
sphorylated form of Rb and the cell cycle regulator, cdc2 (Fig 3C).
In contrast, the SCC25 cells (growth inhibitor insensitive) did not
show any alteration in Rb phosphorylation status or cdc2 protein
levels during a similar time period (Fig 3B). These data con®rmed
that Rb hypophosphorylation and cdc2 downregulation were good
markers of TGF-b1-mediated growth inhibition in keratinocytes.
We now examined whether the regulation of Rb hypopho-
sphorylation was similar to that for 3TP-Lux, i.e., was transcription
dependent. We tested this possibility in human epidermal
keratinocytes by examining the effects of a 12 h exposure to
TGF-b1 on Rb phosphorylation status in the presence or absence
of 250 ng per ml actinomycin D (Saunders et al, 1998). Figure 4
demonstrates that the loss of phosphorylated Rb, in response to
TGF-b1, is inhibited by actinomycin D. As actinomycin D alone
did not signi®cantly perturb the phosphorylation status of Rb these
data suggested that TGF-b1-mediated human epidermal keratino-
cyte growth inhibition operates through a transcription-dependent
signaling pathway. In this regard, the regulation of growth
inhibition by TGF-b1 was similar to the regulation of 3TP-Lux
activation.
TGF-b1 activates SMAD7-sensitive and SMAD7-insensitive
pathways We now examined whether both growth inhibition
and 3TP-Lux activation were SMAD-dependent events. SMAD2-,
SMAD3-, and SMAD4-dependent signaling of 3TP-Lux can be
inhibited by SMAD7 (Nakao et al, 1997; Itoh et al, 1998).
Furthermore, SMAD7 has been shown to be induced in cells
following TGF-b1 treatment (Afrakhte et al, 1998). Therefore, we
examined the expression of SMAD7 following TGF-b1 treatment.
Treatment of human epidermal keratinocytes with TGF-b1 (20 ng
per ml) caused a rapid and time-dependent induction of SMAD7
mRNA that was maximal at 2 h (3.5-fold) and returned to basal
levels by 4 h (Fig 5A). The induction of SMAD7 by TGF-b1
suggests that SMAD7 is likely to be a negative regulator of SMAD
signaling in keratinocytes. We therefore examined the effects of
overexpressing SMAD7 on the ability of TGF-b1 (i) to induce
PAI-1 promoter activity (estimated by 3TP-Lux activation), (ii) to
inhibit the promoter activity of the proliferation-speci®c marker
cdc2, or (iii) to induce the promoter activity of the growth-arrest-
speci®c gene, p21 (Datto et al, 1995). It has been previously shown
that cdc2 promoter activity is both proliferation speci®c (Saunders
et al, 1993a; Saunders and Jetten, 1994; Dahler et al, 1998) and
E2F:Rb regulated (Dalton, 1992; Tommasi and Pfeifer, 1995)
whereas that of the p21 promoter is growth arrest speci®c and
SMAD3, SMAD4, and Sp1 dependent (Datto et al, 1995; Li et al,
1998; Moustakas and Kardassis, 1998). It is also important to note
that p21 inhibits Rb phosphorylation resulting in growth inhibition
(Dyson, 1998). Treatment of keratinocytes with TGF-b1 resulted
in a 6-fold increase in the activity of the 3TP-Lux reporter
construct (Fig 5B). This increase in 3TP-Lux activity was inhibited
3-fold by the cotransfection of a SMAD7 expression plasmid
(Fig 5B). Treatment of keratinocytes with TGF-b1 resulted in a 3-
fold decrease in the activity of the cdc2 promoter (Fig 5C). This is
similar in magnitude to the decrease in cdc2 mRNA expression
reported in keratinocytes following TGF-b1 treatment (Saunders
and Jetten, 1994). Cotransfection of the SMAD7 expression
Figure 2. SCC25 cells express low levels of TGF-b type II receptor
mRNA. Total RNA (30 mg) from proliferating human epidermal
keratinocytes or SCC25 cells was subjected to northern blotting and
probed for mRNA expression levels of the type I (Type I rec) and type II
(Type II rec) TGF-b receptor. The expression of GAPDH was also
estimated to allow for loading inequalities.
Figure 3. SCC25 cells are resistant to TGF-b1-induced Rb hypo-
phosphorylation and cdc2 downregulation. (A) Proliferating human
epidermal keratinocytes and SCC25 cells were treated with TGF-b1 (20 ng
per ml) for varying times at which point DNA synthesis was estimated by
thymidine incorporation (dpm per mg protein). Data are the mean 6 SEM
of at least three determinations expressed as a percentage of the untreated
sample. (B) Human epidermal keratinocytes and SCC25 cells were
harvested for determination of Rb phosphorylation status and cdc2 protein
levels following treatment with TGF-b1 (20 ng per ml) for varying times.
In this instance, proteins were isolated and 20 mg were run on a 7.5% SDS-
PAGE gel and blotted to PVDF membrane. The hypophosphorylated form
(Rb) and the hyperphosphorylated form (RbPP) were detected by their
different mobilities following immunoblotting. The expression levels of the
cdc2 protein are also shown.
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plasmid did not inhibit TGF-b1-mediated cdc2 suppression
(Fig 5C). These data indicate that the signaling pathway
regulating the TGF-b1-mediated suppression of the proliferation-
speci®c marker cdc2 is SMAD7 insensitive. Treatment of
keratinocytes with TGF-b1 resulted in a 3.5-fold increase in the
p21 promoter activity (Fig 5D). The induction of p21 promoter
activity by TGF-b1 was inhibited by cotransfection of SMAD7
(Fig 5D). These data indicate that treatment of keratinocytes with
TGF-b1 initiates events that lead to the suppression or induction of
the critical cell cycle genes, cdc2 and p21, respectively. The data
also show that this regulation is not mediated through the same
signaling pathway, however.
Suppression of TG 1 mRNA expression is SMAD7
sensitive As the suppression of growth and the suppression of
differentiation are functionally distinct outcomes of TGF-b1 action
in keratinocytes we examined whether the suppression of
differentiation by TGF-b1 was defective in the SCC25 cells.
Figure 6 demonstrates that TGF-b1 can inhibit IFN-g- as well as
TPA-mediated induction of TG 1 mRNA expression in
keratinocytes (Fig 6). These data extend our earlier observation
that TGF-b1 could also inhibit IFN-g-induced expression of
another differentiation-speci®c marker, corni®n (Saunders and
Jetten, 1994). As TPA and IFN-g actions are mediated by different
signaling pathways this would suggest that differentiation
suppression is a general property of TGF-b1 in keratinocytes. An
examination of TG 1 mRNA levels in the SCC25 cell line revealed
that, although neither TPA nor IFN-g could induce TG 1 mRNA
levels, the constitutive expression of TG 1 mRNA was suppressed
by TGF-b1 in untreated as well as TPA- or IFN-g-treated SCC25
cells (Fig 6). These data indicate that, unlike the growth inhibitory
Figure 4. TGF-b1-induced hypophosphorylation of Rb is inhibited
by actinomycin D. Proliferating human epidermal keratinocytes were left
untreated (Prol.) or were treated for 12 h with 20 ng per ml TGF-b1 (TGF-
b1), 250 ng per ml actinomycin D (Act. D), or TGF-b1 + actinomycin D
(TGF-b1 + Act. D). The hyphosphorylated (Rb) and hyperphosphorylated
(RbPP) forms of Rb were determined as described in Fig 3.
Figure 5. SMAD7 inhibits 3TP-Lux activation and p21 promoter
activation but not cdc2 promoter suppression. (A) Total RNA was
harvested from human epidermal keratinocytes at various times following
TGF-b1 treatment. Twenty micrograms of total RNA was then
electrophoresed and transferred onto nylon membrane. The expression of
SMAD7 and GAPDH mRNA was detected using speci®c [32P]-labeled
cDNA probes followed by phosphorimage analysis. Data are expressed as
arbitrary expression levels normalized for GAPDH expression. (B)
Proliferating human epidermal keratinocytes were transfected with both
0.3 mg b-actin CAT and 1 mg of 3TP-Lux plus either 0.3 mg of SMAD7
expression vector or the control vector pCDNA3. Cells were then treated
with (+) or without (±) 20 ng per ml TGF-b1 for 48 h. 3TP-Lux was then
normalized for transfection ef®ciency against the b-actin CAT activity and
the data were plotted as a percentage of the value obtained in the absence of
TGF-b1. (C) Human epidermal keratinocytes were treated the same as for
(B) with the exception that the cells were transfected with 1 mg of cdc2-
CAT reporter and 0.3 mg of b-actin Luc. The ratio of reporter to SMAD7
expression plasmid was the same as in (B). (D) Human epidermal
keratinocytes were treated the same as for (B) with the exception that
the cells were transfected with 1 mg of p21 luciferase reporter and 0.3 mg of
b-actin CAT. The ratio of reporter to SMAD7 expression plasmid was the
same as in (B). All data (except A) are presented as mean 6 SEM of
triplicate determinations from three experiments.
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pathways, the signaling pathway regulating differentiation
suppression is intact in the SCC25 cells. This is similar to the
presence of an intact pathway regulating PAI-1 promoter activity
(estimated by 3TP-Lux) in the SCC25 cells.
The mechanism by which TGF-b1 decreases TG 1 mRNA
levels is currently unknown. Consequently, we examined whether
the TGF-b1-mediated suppression of TG 1 mRNA was SMAD7
inhibitable. In the ®rst instance, we examined a time course for the
suppression of TG 1 mRNA in human epidermal keratinocytes
treated with TPA for 36 h (induces differentiation) and then
cotreated with TGF-b1 for varying times to 36 h (Fig 7A). This
experiment indicated that the TG 1 mRNA was rapidly decreased
in the presence of TGF-b1 (t1/2 = 7.9 h). We next examined
whether the suppression of differentiation, as characterized by TG 1
mRNA expression, by TGF-b1 in keratinocytes was SMAD7
inhibitable. To do this, human epidermal keratinocytes were
treated with the differentiation-inducing agent TPA (50 ng per ml)
for 16 h to induce TG 1 mRNA (Dicker et al, in press). Following
this cells were cotransfected with either the pCDNA3 vector or the
SMAD7 expression vector plus CMV-GFP. We had previously
established that under these conditions SMAD7 is able to inhibit
TGF-b1-mediated p21 and 3TP-Lux induction (Fig 5). These cells
were then treated with TPA (50 ng per ml) or TPA (50 ng per ml) +
TGF-b1 (20 ng per ml) for a further 16 h. Cells were then harvested
and the transfected cells (GFP expressing) were sorted by FACS
(approximately 3.5%±5% transfection ef®ciency). RNA was then
isolated from the FACS cells and the expression of TG 1 and actin
mRNA was determined by RT-PCR analysis. Figure 7(B) clearly
shows that TGF-b1 suppresses TG 1 mRNA expression by 90%
whereas overexpression of SMAD7 can prevent this suppression
and in fact leads to 2-fold greater levels of expression of TG 1
mRNA. These data indicate that TGF-b1-mediated TG 1
suppression is SMAD7 inhibitable.
DISCUSSION
In this study we have examined the signaling pathways involved in
the regulation of markers of differentiation, ECM production, and
proliferation in response to TGF-b1 in primary cultures of human
keratinocytes. Our data suggest that multiple TGF-b signaling
pathways exist in keratinocytes and that these may be linked to the
regulation of different biologic functions (Fig 8). In this study we
found that TGF-b1-mediated growth inhibition of human
epidermal keratinocytes was associated with two functionally
distinct pathways. In the ®rst instance TGF-b1 induced the
expression of the established growth suppressor, p21 (Datto et al,
1995). The induction of p21 was mediated by a SMAD7-
inhibitable pathway, which is consistent with reports that p21
induction is mediated by SMAD3, SMAD4 interacting with the
transcription factor Sp1 in the p21 promoter (Moustakas and
Kardassis, 1998). In contrast, TGF-b1 also suppressed the activity of
the cdc2 promoter. cdc2 is also a well-established cell cycle
regulator that is essential for cell division (Lee and Nurse, 1987;
Heuvel and Harlow, 1993; Dahler et al, 1998). The inability of
SMAD7 to inhibit TGF-b1-mediated suppression of cdc2
promoter activity occurred at a concentration of SMAD7 that we
had shown could inhibit 3TP-Lux activation, TG 1 suppression,
and p21 induction. These data suggest that TGF-b1 induces
growth arrest by initiating a cascade of events (both SMAD7-
Figure 6. Suppression of TG 1 mRNA expression by TGF-b1
occurs in both human epidermal keratinocytes and SCC25 cells.
Human epidermal keratinocytes or SCC25 cells were either left untreated
(Prol.) or treated for 48 h with TGF-b1 (20 ng per ml), TPA (50 ng per ml),
IFN-g (100 U per ml), or a combination of TPA + TGF-b1 or IFN-
g + TGF-b1. Following incubations, total RNA was harvested and 20 mg
fractionated by electrophoresis and transferred to nylon membrane.
Membranes were then probed for expression of either TG 1 or GAPDH.
Figure 7. Time-dependent suppression of TG 1 by TGF-b1. (A)
Expression of TG 1 in human epidermal keratinocytes that have been
treated with 50 ng per ml TPA for 24 h to induce differentiation followed
by treatment with TPA + TGF-b1 (20 ng per ml) for various times. Total
RNA was isolated and 20 mg subjected to northern blotting and probed for
TG 1 and GAPDH expression. Expression was quantitated by densitometry
and TG 1 expression was normalized for GAPDH expression to that of
GAPDH by densitometry. (B) Human epidermal keratinocytes were
induced to differentiate by treatment with TPA (TPA; 50 ng per ml) for
16 h. Cells were then transfected with expression vectors encoding nothing
(pCDNA3) or SMAD7 (SMAD7) and treated with TGF-b1 (TGF-b1;
20 ng per ml) for 16 h. All cells were cotransfected with a GFP-expressing
plasmid. Transfected cells expressing GFP were then FACS sorted and the
expression of TG 1 and actin mRNA was determined by RT-PCR in the
transfected human epidermal keratinocytes. The expression of TG 1
mRNA is presented as a percentage of the TG 1 mRNA expression in the
TPA differentiated keratinocytes. TG 1 mRNA expression levels have been
normalized for actin mRNA expression.
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sensitive and SMAD7-insensitive) that leads to the suppression of
the cell cycle. Evidence of multiple signaling pathways involved in
TGF-b1-induced growth suppression is also supported by our
observations that both the human epidermal keratinocytes and
SCC25 cells could regulate TG 1 suppression and 3TP-Lux
induction in response to TGF-b1 whereas the SCC25 cells were
not growth inhibited by TGF-b1 and did not accumulate
hypophosphorylated Rb in response to TGF-b1. The inability of
TGF-b1 to inhibit growth of SCC25 cells occurred despite the fact
that they express p21 protein but not p53 (unpublished observa-
tions). Moreover, the SCC25 cells did not express detectable levels
of type II TGF-b receptor mRNA, which has previously been
suggested to regulate growth inhibitory responses to TGF-b1
(McCaffrey et al, 1995). In addition, the dose±response pro®le for
the activation of the 3TP-Lux in human epidermal keratinocytes
revealed an Ec50 value (0.41 6 0.16 ng per ml) that was almost an
order of magnitude less than that for growth suppression
(3.2 6 1.3 ng per ml). These observations strongly implicate a
complex signaling pathway involved in growth inhibition.
The mechanism by which TGF-b1 mediates growth suppression
in human epidermal keratinocytes was not addressed in this study as
it has been the subject of extensive work previously (Hannon and
Beach, 1994; Datto et al, 1995; Li et al, 1995; Reynisdottir et al,
1995; Iavarone and Massague, 1997; Nagahara et al, 1999). Our
data clearly demonstrate, however, that TGF-b1-mediated growth
suppression is associated with a suppression of cdc2 protein levels
and promoter activity, an induction of p21 promoter activity, and
the accumulation of hypophosphorylated Rb. Rb is a known target
of TGF-b1 action and is also a key regulator of E2F-mediated G1/S
phase transition (Dyson, 1998). Furthermore, previous studies have
shown that TGF-b1 can induce p21 (Datto et al, 1995) and p15
(Hannon and Beach, 1994; Li et al, 1995) and repress cdc25a
(Iavarone et al, 1997) or cyclinE:cdk2 activity (Nagahara et al,
1999), all of which ultimately affect E2F activity. Thus, our data are
consistent with earlier reports in which Rb and E2F activity were
the downstream effectors of TGF-b-mediated growth inhibition.
Our study extends these ®ndings, however, and suggests that a
SMAD7-independent pathway may also be invoked during TGF-
b1-mediated growth suppression. This pathway is characterized by
the downregulation of cdc2 in response to TGF-b1. Although the
signaling events mediating cdc2 suppression are unknown it is clear
that this process is not downstream of the cell cycle arrest caused by
p21 induction and Rb hypophosphorylation as cdc2 suppression is
SMAD7 insensitive whereas that of p21 induction is SMAD7
inhibitable.
The inability of SMAD7 to inhibit TGF-b1-mediated cdc2
suppression as well as the inability of SCC25 cells to undergo
growth arrest in response to TGF-b1 suggests that the transcrip-
tional suppression of cdc2 may be regulated by different domains
on the type I or II TGF-b receptors to those mediating SMAD-
dependent 3TP-Lux activation, p21 induction, or TG 1 suppres-
sion. This has not been shown in keratinocytes previously but is
consistent with earlier data in which growth suppression and PAI-1
activation were dissociated in cells in which the type II receptor
was truncated or poorly expressed (Chen et al, 1993; McCaffrey
et al, 1995). Our ®nding of negligible expression of the type II
receptor mRNA in the SCC25 cells is consistent with this view and
may indicate a role for the type II receptor in TGF-b1-mediated
cdc2 suppression in keratinocytes. Further evidence supporting an
independent role for the type II receptor in TGF-b signaling comes
from earlier reports in which SMAD7 inhibited PAI-1 activation
by inhibiting the binding of SMAD2 or SMAD3 to the type I
receptor (Hayashi et al, 1997; Nakao et al, 1997). Thus, our data
suggest that suppression of cdc2 is mediated by a pathway requiring
a different domain on the type I receptor to that required for PAI-1
activation or that the signaling pathway is initiated from the type II
receptor.
It has been reported previously that TGF-b1-mediated growth
inhibition of B cells by activin (Ishisaki et al, 1998) and MvLu1 cells
by TGF-b1 (Itoh et al, 1998) is attenuated (not abolished) by
SMAD7. Although we did not speci®cally examine the effects of
SMAD7 on TGF-b1-mediated growth suppression in this study we
did show that TGF-b1-mediated growth inhibition involves both
induction of a growth inhibitor, p21, as well as suppression of a
proliferation-speci®c gene, cdc2. Both of these TGF-b1-dependent
events would be expected to be growth inhibitory. Thus, the
inability of SMAD7 to totally abolish TGF-b1-mediated growth
suppression in earlier studies (Ishisaki et al, 1998; Itoh et al, 1998)
may be due to the residual growth inhibitory activity mediated by a
SMAD7-independent pathway. Although cdc2 has been reported
to be involved in S phase entry (Itzhaki et al, 1997) it is primarily
thought to be involved in a G2/M phase arrest. TGF-b1 treatment
is generally associated with a G1 arrest (Nagahara et al, 1999)
although it has also been reported to induce a G2 arrest in
keratinocytes (Shipley et al, 1986). The exact mechanism of the
TGF-b1-induced G2 arrest in keratinocytes is unclear but is
consistent with our ®ndings. It is interesting to note that a recent
report suggested that cyclinB:cdc2 could bind to the type II TGF-b
receptor and was inactivated by TGF-b treatment (Liu et al, 1999).
Although it is unknown whether this interaction occurs in
keratinocytes it is consistent with the ®nding that the SCC25 cells
do not undergo growth arrest in response to TGF-b1 and do not
express type II receptor mRNA. Regardless of the role of cdc2
suppression in TGF-b1-mediated actions our data clearly show (i)
that TGF-b1 induces a transcriptional suppression of cdc2 and (ii)
that this suppression is mediated by an unknown and SMAD7-
insensitive signaling pathway.
Alternatively, the SMAD7-insensitive pathway of cdc2 suppres-
sion may play an important role in other TGF-b1-mediated actions
such as the maintenance of genome stability (Glick et al, 1999).
TGF-b1-induced stabilization of the genome was reported to occur
at a dose of TGF-b1 that was lower than that required for growth
suppression. Such a ®nding is consistent with the existence of
multiple TGF-b1 signaling pathways in keratinocytes. It would be
interesting to examine whether this pathway is SMAD7 sensitive or
not.
Figure 8. Proposed signaling pathway med-
iating TGF-b1 actions in human keratino-
cytes. The proposed pathway links TGF-b1-
mediated suppression of differentiation and induc-
tion of PAI-1 and p21 to the SMAD7-inhibitable
pathway. In contrast, the inhibition of cdc2 is hy-
pothesized to be mediated by a ligand/receptor-
dependent but SMAD7-insensitive pathway.
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We had previously reported that TGF-b1 was able to inhibit
IFN-g-induced expression of the squamous differentiation-speci®c
markers TG 1 and corni®n (Saunders and Jetten, 1994). In this
study we extend these ®ndings to show that TGF-b1 can suppress
the expression of the differentiation-speci®c marker TG 1
following either TPA- or IFN-g-induced differentiation in
keratinocytes. Furthermore, we show that the constitutive expres-
sion of TG 1 by SCC25 cells can also be suppressed by TGF-b1.
This suppression is presumed to be transcriptional as we were
unable to show any alteration in TG 1 mRNA stability in response
to TGF-b1 (data not shown). It remains unclear, however, whether
the suppression of TG 1 is mediated directly by SMAD
transcription factors, as it is for PAI-1 induction, or whether TG
1 suppression is mediated by events downstream of SMAD-
dependent transcriptional activation. It is of interest to note that a
reporter construct containing the proximal 2.9 kb of the transglu-
taminase type 1 promoter could not be suppressed by TGF-b1 in
differentiated keratinocytes (data not shown), although this region
of the promoter was recently shown to contain suf®cient elements
to direct transcription in a tissue-speci®c and differentiation-
speci®c manner in transgenic mice (Medvedev et al, 1999). These
data would suggest that the TGF-b1-rsponsive elements must lie
outside this 2.9 kb region. Notwithstanding this, our data clearly
show that proximate signaling events controlling PAI-1 induction
and TG 1 suppression are similar as they are both inhibited by
SMAD7.
An examination of the signaling pathways responsible for TGF-
b1 actions in normal keratinocytes provides insight into the role of
TGF-b1 in neoplastic progression. For instance, recent studies (Cui
et al, 1996; Portella et al, 1998) have demonstrated that during
neoplasia the disruption of TGF-b1 actions occurs in two distinct
phases. In the ®rst instance, the loss of TGF-b1-mediated growth
suppression occurs. In contrast, the second phase of transformation
to a malignant spindle cell carcinoma is actually induced by TGF-
b1 (Cui et al, 1996). These apparently contradictory ®ndings may
re¯ect the presence of defects at different points downstream of
TGF-b1 signaling that are associated with different functional
outcomes or signaling pathways.
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